康艾注射液对结肠癌患者IL-17和IL-10表达的影响以及临床疗效分析

The effect of Kang'ai injection on IL-17 and IL-10 expression in patients with colon cancer and its clinical efficacy

[目的]观察化疗联合康艾注射液对晚期结肠癌患者白介素-17（IL-17）和白介素-10（IL-10）表达的影响并分析其临床疗效。[方法]选取2013年2月-2015年9月我院消化内科治疗的晚期结肠癌患者92例,使用数字法随机分为常规化疗对照组和康艾注射液联合化疗观察组,每组46例。ELISA法检测IL-17和IL-10表达。比较2组临床疗效和不良反应发生率。[结果]2组治疗前IL-17和IL-10表达水平差异无统计学意义（P〉0.05）,治疗后2组IL-17表达水平均显著减低,IL-10表达水平显著升高（P〈0.05和P〈0.01）,但观察组IL-17表达水平的减低作用以及IL-10表达水平的升高作用显著优于对照组（P〈0.05）。观察组治疗有效率为87.0%,显著高于对照组的71.7%（P〈0.05）。观察组不良反应发生率为41.3%,显著低于对照组的72.3%（P〈0.05）。[结论]康艾注射液调节了结肠癌患者IL-17/IL-10平衡紊乱,提高了患者的临床疗效,减低了药物不良反应发生率,具有一定的临床应用价值。

[Objective]To detect the effect of Kang＇ai injection on IL-17 and IL-10 expression in patients with colon cancer and its clinical efficacy.[Methods]Ninety-two cases of colon cancer patients were enrolled in this study.Patients were randomly divided into control group（n=46）and Kang＇ai injection observation group（n=46）.IL-17 and IL-10 expression was detected by ELISA analysis.The clinical effect and incidence of adverse reaction were compared between the two groups.[Results]Before treatment,there was no significant difference in the expression of IL-17 and IL-10 between the two groups（P〉0.05）.After treatment,the expression of IL-17 was lower and IL-10 was higher in observation group than that in control group（P〈0.05 and P〈0.01）.The clinical effect rate in observation group was 87.0%,which was higher than that of 71.7%in control group（P〈0.05）.The incidence of adverse reaction was 41.3%in observation group,which was lower than that of 72.3%in control group（P〈0.05）.[Conclusion]Kang＇ai injection could regulate the balance of IL-17/IL-10 in colon cancer patients,improve the clinical effect and reduce the incidence of adverse reactions.